Senior management will conduct a series of presentations to update analysts and investors on the Company’s ongoing clinical development programs. In addition, a key opinion leader will provide a clinical perspective on respiratory syncytial virus (RSV) disease.

Novavax expects to announce data from its pivotal Phase 3 trial of the RSV F Vaccine in older adults in the third quarter of 2016.